Crohn’s Disease | China In-Depth | 2025
The Crohn’s disease (CD) therapy market in China is growing rapidly due to the increased prevalence of the disease as a result of urbanization, dietary changes, and better diagnostics. Corticosteroids are essential for managing acute flares, and immunosuppressants are used for long-term maintenance, often alongside biologics. Biologics, particularly anti-TNF agents such as Johnson & Johnson Innovative Medicine’s Remicade and AbbVie/Eisai’s Humira, are widely used to treat moderate to severe CD. Non-TNF biologics such as Takeda’s Entyvio and Johnson & Johnson Innovative Medicine’s Stelara are options for patients who do not respond to anti-TNF treatment. Recent approvals (e.g., AbbVie’s Skyrizi) and emerging therapies with novel mechanisms of action (e.g., Eli Lilly’s Omvoh, Johnson & Johnson Innovative Medicine’s Tremfya) will expand the treatment armamentarium. This report assesses how clinical and nonclinical factors—such as price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL), and generics or biosimilars—will influence the launch and uptake of key therapies for CD. Understanding these factors will be crucial for the success of current and future players in this lucrative market.
Questions answered
- What is the size of China’s diagnosed CD population, and how will drug-treatment rates change over the forecast period?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of CD in China?
- What are the key market access considerations for therapies in the CD pipeline in China?
- What sales / uptake could they secure?
Primary research
Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 gastroenterologists in China.
Epidemiology
Diagnosed prevalence of Crohn’s disease in urban versus rural China, clinically relevant and market-relevant drug-treatable populations.
Forecast
10-year, annualized, drug-level sales and patient share of key Crohn’s disease therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions.
Drug treatments
Coverage of key current and late-phase emerging therapies.
Product description
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events
